About Ascendo
Our novel approach optimizes and reinvigorates the natural, innate immune pathways to deliver comprehensive anti-tumor responses and restore immune balance in autoimmune diseases. With each new therapy, we aim to overcome the limitations of existing treatments and achieve meaningful, lasting benefits for patients across oncology and immunology.
ASD141 is a novel, innate immune checkpoint inhibitor that commands the innate immune system to coordinate a renewed attack on solid tumors. Alongside it, ASD001 targets autoimmune diseases by rebalancing overactive myeloid cells through selective innate immune modulation. Together, these first-in-class therapeutics represent a diverse pipeline focused on impactful innovation in both immuno-oncology and autoimmune indications.
Our Mission
Our mission is to create next-generation immunotherapies that deliver transformative benefits to patients worldwide.
Our research and innovation strategy centers on discovering and developing groundbreaking therapies that redefine the treatment landscape for cancer and autoimmune diseases. With a deep focus on innate immunity, we aim to unlock new therapeutic pathways that overcome the limitations of current treatments.
ASD141, our lead innate immune checkpoint inhibitor, activates the body’s natural defenses against solid tumors by reshaping the tumor microenvironment and enhancing anti-tumor immune responses. ASD001, our autoimmune-focused antibody therapy, reprograms overactive immune cells to restore immune balance and reduce inflammation in diseases such as lupus and inflammatory bowel disease.
While we pursue high-value clinical candidates that drive sustainable growth, our core commitment remains creating impactful therapies that help people live healthier, longer lives.
“We are breaking through the limitations of current immunotherapies to enable access for more patients than ever before.”
Breakthrough Science
Our lead product, ASD141, is a powerful immunotherapy targeted to optimize the complex interactions between the innate and the adaptive immune system.
ASD141 works by blocking TLT-1, a key regulatory protein that induces the immune suppressive environment in the tumor. Blocking TLT-1 binding to receptor CD11b reinvigorates the innate cells that coordinate an immune response in the tumor microenvironment. Our anti-TLT-1/CD11b approach has infinite potential to be used both as monotherapy and to help improve the safety and efficacy of existing treatments when used in combination.
Our Team
Our expert team specialise in immunotherapy-focused drug development, immunology, and innate immune research.
Find out more here:
About Us
Partner of choice for novel immunotherapeutics
Ascendo Biotechnology is a strategic partner of choice for novel immunotherapies which exploit the interplay between the innate and adaptive immune response. We are currently seeking partners to accelerate the development and commercialization of our lead oncology drug, ASD141.
If you’re interested in discussing our programmes, please get in touch: